Serodus ASA is a Scandinavian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs.Serodus strives to increase shareholders value through advancing its portfolio to value-creating clinical milestones. With the current drug candidates supported by exceptional competencies to develop them, Serodus is uniquely positioned for success

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The company focuses on new and effective solutions within wound care, cancer therapies and other immune related disease areas, and aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.

The Sarsia Seed Management team comes from a wide variety of backgrounds with a collective expertise which is extensive not only with respect to the various investment areas on which the fund focuses, but also with respect to best practice/effective fund administration.